High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events

被引:18
|
作者
Romano, Kara D. [1 ]
Hill, Colin [1 ]
Trifiletti, Daniel M. [1 ]
Peach, M. Sean [1 ]
Horton, Bethany J. [2 ]
Shah, Neil [1 ]
Campbell, Dylan [1 ]
Libby, Bruce [1 ]
Showalter, Timothy N. [1 ]
机构
[1] Univ Virginia, Dept Radiat Oncol, Sch Med, 1240 Lee St,Box 800383, Charlottesville, VA 22908 USA
[2] Univ Virginia, Sch Med, Div Translat Res & Appl Stat, Dept Publ Hlth Sci, Charlottesville, VA 22908 USA
关键词
IMAGE-GUIDED BRACHYTHERAPY; SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA; AMERICAN BRACHYTHERAPY; ADAPTIVE BRACHYTHERAPY; WORKING GROUP; VOLUME; DELINEATION; PARAMETERS; SURVIVAL;
D O I
10.1186/s13014-018-1074-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brachytherapy (BT) is a vital component of the curative treatment of locally advanced cervical cancer. The American Brachytherapy Society has published guidelines for high dose rate (HDR) BT with recommended dose limits. However, recent reports suggest lower doses may be needed to avoid toxicity. The purpose of this study is to investigate incidence and predictive factors influencing gastrointestinal (GI) and genitourinary (GU) toxicity following HDR intracavitary brachytherapy for locally advanced cervical cancer. Methods: We retrospectively evaluated a cohort of patients with locally advanced cervical cancer who received CT-based HDR BT. Cumulative doses were calculated using the linear-quadratic model. Statistical analyses were used to investigate clinical and dosimetric predictors of GI and GU toxicity following HDR brachytherapy according to CTCAE v4.0 grading criteria. Results: Fifty-six women with FIGO IB1 - IVA cervical cancer were included. The overall rate of any GU adverse event (Grade 1+) was 23.3% (n = 13) and severe adverse events (Grade 3+) was 7.1% (n = 4). Of those, the bladder equivalent dose in 2- Gray (Gy) fractions (EQD(2)) D-2cc was >= 80 for three of the four patients. The overall rate of any GI adverse event was 26.8% (n = 15) and the rate of severe adverse events was 14.3% (n = 8). Of those, six of the eight patients had a rectal EQD(2) D-2cc >= 65 Gy and seven patients had a sigmoid D-2cc >= 65 Gy. Amongst clinically meaningful factors for development of adverse events (i.e. diabetes, smoking status, ovoid size, and treatment duration), there were no statistically significant prognostic factors identified. Conclusions: Severe adverse events are observed even with adherence to current ABS guidelines. In the era of recent multi-institutional study results, our data also supports more stringent dosimetric goals. We suggest cumulative D2cc dose limits of less than 80 Gy for the bladder and less than 65 Gy for the rectum and sigmoid.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] High dose-rate tandem and ovoid brachytherapy in cervical cancer: dosimetric predictors of adverse events
    Kara D. Romano
    Colin Hill
    Daniel M. Trifiletti
    M. Sean Peach
    Bethany J. Horton
    Neil Shah
    Dylan Campbell
    Bruce Libby
    Timothy N. Showalter
    Radiation Oncology, 13
  • [2] An Automated Treatment Plan Quality Assurance Program for Tandem and Ovoid High Dose-Rate Brachytherapy
    Tan, J.
    Shi, F.
    Hrycushko, B.
    Medin, P.
    Stojadinovic, S.
    Pompos, A.
    Yang, M.
    Albuquerque, K.
    Jia, X.
    MEDICAL PHYSICS, 2015, 42 (06) : 3594 - 3594
  • [3] On the Importance of Inverse Treatment Planning in High-Dose-Rate Brachytherapy with a Tandem-And-Ovoid Applicator for Cervical Cancer
    Gonzalez, Y.
    Shen, C.
    Klages, P.
    Albuquerque, K.
    Jia, X.
    MEDICAL PHYSICS, 2018, 45 (06) : E482 - E483
  • [4] Dosimetric Comparison of Freehand and Template Interstitial Needle Insertion with Tandem and Ovoid Applicator for High Dose Rate Brachytherapy
    Washington, B. T.
    Yarlagadda, P.
    Iqbal, Z.
    Medin, P. M.
    Hrycushko, B. A.
    Owrangi, A. M.
    Albuquerque, K.
    Gonzalez, Y.
    MEDICAL PHYSICS, 2024, 51 (10) : 7822 - 7822
  • [5] High dose-rate brachytherapy for elderly patients with uterine cervical cancer
    Chen, SW
    Liang, JA
    Yang, SN
    Lin, FJ
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2003, 33 (05) : 221 - 228
  • [6] HIGH DOSE-RATE INTRACAVITARY BRACHYTHERAPY IN ELDERLY WOMEN WITH CERVICAL CANCER
    Melo, M.
    Novaes, P.
    Balloni, H.
    Teixeira, G.
    Castro, D.
    Salvajoli, J. V.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S186 - S187
  • [7] High Dose-rate Intracavitary Brachytherapy in Elderly Patients with Cervical Cancer
    Balloni, H.
    Melo, M. D.
    Novaes, P. E. R. S.
    Salvajoli, J. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S374 - S374
  • [8] High and low dose-rate brachytherapy for cervical carcinoma
    Orton, CG
    ACTA ONCOLOGICA, 1998, 37 (02) : 117 - 125
  • [9] High Dose-Rate Versus Low Dose-Rate Brachytherapy for Lip Cancer
    Ghadjar, Pirus
    Bojaxhiu, Beat
    Simcock, Mathew
    Terribilini, Dario
    Isaak, Bernhard
    Gut, Philipp
    Wolfensberger, Patrick
    Broemme, Jens O.
    Geretschlaeger, Andreas
    Behrensmeier, Frank
    Pica, Alessia
    Aebersold, Daniel M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 83 (04): : 1205 - 1212
  • [10] Dosimetric Comparison of Tandem and Ovoid (TO) Vs. Tandem and Ring (TR) Applicators in High-Dose Rate (HDR) Brachytherapy (BT) for the Treatment of Locally-Advanced Cervical-Cancer
    Kuo, L.
    Viswanathan, A.
    Damato, A.
    MEDICAL PHYSICS, 2015, 42 (06) : 3404 - 3404